Literature DB >> 788431

Biological effects of a new and potent progestagen. A clinical study.

L Viinikka, O Ylikorkala, S Nummi, P Virkkunen, T Ranta, U Alapiessa, R Vihko.   

Abstract

The biological effects of a new synthetic progestagen, Org 2969 (13-ethyl-11-methylene-18,19-dinor-17 alpha-pregn-4-en-20-yn-17-ol) were studied in healthy normally menstruating women. Two of them were given 0.125 mg, five 0.060 mg and two 0.030 mg of Org 2969 daily on days 1-20 during one menstrual cycle. Serum levels of follicle stimulating hormone, luteinizing hormone, progesterone and oestradiol were analyzed on days 8-23 in order to evaluate the function of the hypophyseal-ovarian axis. The serum concentrations of aspartate amino transferase, alanine amino transferase, alkaline phosphatase, gamma glutamyl transpeptidase and bilirubin were determined to evaluate possible side effects on live function on days 8, 15 and 23. Serum cortisol was measured on days 8 and 23. The basal body temperature was recorded daily during the whole cycle, and endometrium biopsies were taken on days 21 or 22 of the cycle. All samples were taken similaryl during the treatment cycle and the preceding control cycle. According to the hormone determinations, all the treatment cycles were anovulatory except in one woman receiving the lowest dose. The treatment led to decreased spinnbarkeit, arborization and sperum penetration in the cervical mucus. Liver function tests and serum cortisol remained unchanged during the treatment.

Entities:  

Mesh:

Substances:

Year:  1976        PMID: 788431     DOI: 10.1530/acta.0.0830429

Source DB:  PubMed          Journal:  Acta Endocrinol (Copenh)        ISSN: 0001-5598


  5 in total

1.  The role of CYP2C and CYP3A in the disposition of 3-keto-desogestrel after administration of desogestrel.

Authors:  Tuomas Korhonen; Ari Tolonen; Jouko Uusitalo; Stefan Lundgren; Jorma Jalonen; Kari Laine
Journal:  Br J Clin Pharmacol       Date:  2005-07       Impact factor: 4.335

2.  Metabolism of a new synthetic progestagen, Org 2969, in female volunteers. Pharmacokinetics after an oral dose.

Authors:  L Viinikka; O Ylikorkala; R Vihko; H P Wijnand; M Booij; F van der Veen
Journal:  Eur J Clin Pharmacol       Date:  1979-06-12       Impact factor: 2.953

3.  Metabolism of the contraceptive steroid desogestrel by the intestinal mucosa.

Authors:  S Madden; D J Back; C A Martin; M L Orme
Journal:  Br J Clin Pharmacol       Date:  1989-03       Impact factor: 4.335

Review 4.  Pharmacokinetics, metabolism and serum concentrations of progestins used in contraception.

Authors:  Alexis J Bick; Renate Louw-du Toit; Salndave B Skosana; Donita Africander; Janet P Hapgood
Journal:  Pharmacol Ther       Date:  2020-12-13       Impact factor: 13.400

5.  The influence of bariatric surgery on oral drug bioavailability in patients with obesity: A systematic review.

Authors:  Philip Carlo Angeles; Ida Robertsen; Lars Thomas Seeberg; Veronica Krogstad; Julie Skattebu; Rune Sandbu; Anders Åsberg; Jøran Hjelmesaeth
Journal:  Obes Rev       Date:  2019-06-24       Impact factor: 9.213

  5 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.